Evidence map›Paper›PMID 42122259›Full record

ReviewCancers2026

The HGF/MET Axis in Advanced Prostate Cancer: From Context-Dependent Biology to Biomarker-Driven Therapeutic Strategies.

Filippos Koinis, Maria Smaragdi Vlachou, Georgios Nintos, Georgios Christodoulopoulos, Emmanouil Panagiotidis, Ioannis Eleftheropoulos, Galatea Kallergi, Michail Samarinas, Athanasios Kotsakis

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Filippos KoinisLaboratory of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, GR-41110 Larissa, Greece.ORCID 0000-0001-5495-3331
Maria Smaragdi VlachouDepartment of Medical Oncology, University General Hospital of Larissa, 41110 Larissa, Greece.
Georgios NintosDepartment of Medical Oncology, University General Hospital of Larissa, 41110 Larissa, Greece.
Georgios ChristodoulopoulosDepartment of Medical Oncology, University General Hospital of Larissa, 41110 Larissa, Greece.
Emmanouil PanagiotidisDepartment of Nuclear Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece.ORCID 0000-0002-8501-3905
Ioannis EleftheropoulosDepartment of Urology, General Hospital Asklipieion of Voula, 16673 Voula, Greece.
Galatea KallergiLaboratory of Biochemistry and Metastatic Signaling, Department of Biology, University of Patras, 26504 Patras, Greece.ORCID 0000-0001-9825-3871
Michail Samarinas2nd Department of Urology, Medical School, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Athanasios KotsakisLaboratory of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, GR-41110 Larissa, Greece.ORCID 0000-0002-5530-6774

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

aggressive prostate cancerAR-indifferentbiomarkerscabozantinibMET pathwayprecision medicineprostate cancertargeted treatment

Identifiers

PMID42122259
PMCPMC13162814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.